Loretta J. Nastoupil, MD, MD Anderson Cancer Center

Ongoing Issues in CAR T-Cell Therapy and Lymphoma

July 2nd 2020

Developing CAR T-Cell Trials

July 2nd 2020

Allogenic CAR T-Cell Therapy in Lymphoma

July 2nd 2020

CAR T-Cell Therapy’s Future for Lymphoma

July 2nd 2020

CAR T Cells and Lymphoma Adverse Events

July 2nd 2020

LBCL Therapy: The Right Therapy

July 2nd 2020

R/R NHL: Candidate Identification and Referrals

July 2nd 2020

CAR T-Cell Therapy for Follicular Lymphoma

July 2nd 2020

ZUMA-2 Trial Overview: Mantle Cell Lymphoma Impact

July 2nd 2020

LDH and ECOG Performance Tests

July 2nd 2020

Liso-cel Therapy in R/R Large B-Cell Lymphoma

July 2nd 2020

The Importance of Antigen Loss in R/R Disease

July 2nd 2020

R/R Large B-Cell Therapy in Managing Various Lymphomas

July 2nd 2020

CAR T-Cell Therapy in Managing Various Lymphomas

July 2nd 2020

Rationale for Further Development of CAR T-Cell therapy

July 2nd 2020

Dr. Nastoupil on Efficacy With Pembrolizumab and Rituximab in Follicular Lymphoma

August 28th 2017

Loretta J. Nastoupil, MD, Department of Lymphoma and Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses efficacy findings of a study investigating the combination of pembrolizumab (Keytruda) and rituximab (Rituxan) in patients with relapsed follicular lymphoma.

Dr. Nastoupil on Questions Surrounding TGR1202 in Patients With CLL

August 21st 2017

Loretta J. Nastoupil, MD, Department of Lymphoma and Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the questions researchers are currently facing with TGR1202 in patients with chronic lymphocytic leukemia (CLL).

Dr. Nastoupil on Triplet of TGR1202, Ublituximab, and Ibrutinib in CLL

August 10th 2017

Loretta J. Nastoupil, MD, Department of Lymphoma and Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses an early-phase trial looking at the triplet regimen of TGR1202, ublituximab, and ibrutinib (Imbruvica) in patients with chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL).

Dr. Nastoupil on Pembrolizumab Plus Rituximab in Relapsed Follicular Lymphoma

June 15th 2017

Loretta J. Nastoupil, MD, associate professor, Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses high response rates with prembrolizumab (Keytruda) in combination with rituximab (Rituxan) in patients with relapsed follicular lymphoma.

Dr. Nastoupil on Future Treatment Approaches in Large Cell Lymphoma

October 29th 2016

Loretta J. Nastoupil, MD, an assistant professor in the Department of Lymphoma/Myeloma at The University of Texas MD Anderson Cancer Center, discusses what treatment approaches she sees on the horizon in the landscape of large cell lymphoma. Nastoupil shared this insight in an interview during the 2016 OncLive State of the Science on Hematologic Malignancies.